23andMe, the personal genomics company, went public in early 2021 via a merger with a blank check company that valued it at $3.5 billion. Then its fortunes began to sink. Fading interest in DNA kits – 23andMe's main product – was one driver. So was news last year that hackers stole ancestry data on 6.9 million of its users. CEO and co-founder Anne Wojcicki now reportedly wants to take the 18-year-old company private. After her own proposal to buy it was rebuffed by its board in July, she was given time to w ...

Anne Wojcicki, co-founder and chief executive officer of 23andme Inc., during the South by Southwest (SXSW) festival in Austin, Texas, US, on Friday, March 10, 2023. All seven independent directors of 23andMe resigned from the company's board Tuesday, a move that CEO Anne Wojcicki said left her "surprised and disappointed," according to a memo to employees. Wojcicki, who co-founded 23andMe in 2006, said she remains committed to taking the company private. The genetic-testing company went public in 2021 thro ...

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2024 (GLOBE NEWSWIRE) -- The independent directors of the Board of 23andMe Holding Co. (Nasdaq: ME), today sent the following letter to Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, in which the independent directors have provided their resignation from the Board, effective immediately: Dear Anne, We, the independent directors of the 23andMe Board, hereby tender our resignations, effective immediately. After months ...

23andMe will reportedly pay $30 million to settle a lawsuit tied to a data breach. As Reuters reported Friday (Sept. 13), the genetics testing company has also agreed to provide three years of security monitoring as a result of the class-action litigation, which accused 23andMe of failing to protect the private information of almost 7 million customers exposed in the breach last year. The settlement also resolves allegations that 23andMe did not tell customers with Chinese and Ashkenazi Jewish ancestry that ...

23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression of CD200 and human genetics correlated with increased clinical benefit, suggesting potential value as patient selection biomarkers Greater response in "cold" tumors suggests opportunity in patients unable to benefit from PD-1/PD-L1 checkpoint inhibitors SUNNYVALE, Calif., Sept. 15, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME ...

23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and a subset of adenocarcinomas, offering potential indications to assess clinical activity Phase 1 trial ongoing with first patient dosed in March 2024 SUNNYVALE, Calif., Sept. 15, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company, announced ...

SUNNYVALE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, in collaboration with lead researchers at National Human Genome Research Institute, part of the National Institutes of Health (NIH), and Johns Hopkins University, conducted one of the largest and most diverse studies on sickle cell trait (SCT). Many prior SCT research studies have only focused on Black/African American populations. This collaborative resea ...

Preliminary data from renal cancer and TMB-H/MSI-H cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented Analysis of CD200 as an exploratory tissue-based biomarker associated with 23ME-00610 efficacy to be presented Preclinical murine data on 23ME-01473 to be presented; Phase 1/2a dose escalation study ongoing SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced t ...

Financial Data and Key Metrics - Revenue for Q1 2025 was $40 million, a 34% decrease YoY, primarily due to the conclusion of the GSK collaboration and lower consumer services revenue [15] - Gross profit for the quarter was $21 million, a 33% decrease YoY, driven by lower research data revenue, partially offset by improvements in membership and telehealth margins [16] - Net loss for the quarter was $69 million, an improvement from a net loss of $105 million in the prior year, driven by reduced stock-based compensation and lower GSK collaboration expenses [18] - Adjusted EBITDA deficit for Q1 was $35 million, compared to a $50 million deficit in the prior year, reflecting cost discipline and investment prioritization [19] - Cash and cash equivalents at the end of the quarter were $170 million, down from $216 million as of March 31, 2024 [19] Business Line Data and Key Metrics - Consumer services revenue represented 97% of total revenue, with research data revenue accounting for 3% [16] - Membership revenue growth improved YoY, with better retention metrics, higher upgrade rates, and increased lifetime value (LTV) in telehealth [8] - The company launched a GLP-1 weight loss telehealth membership on the Lemonaid Health platform, aiming to enhance preventive health services [7] - The research data business collaborated on a lung cancer study and published findings on the LRRK2 gene in Parkinson's disease, leveraging its large database [9][10] Market Data and Key Metrics - The company is focusing on improving membership offerings, including adding polygenic risk score reports and a biological age feature [7][8] - A collaboration with Nightingale Health aims to pilot a metabolomics blood biomarker panel, potentially enhancing health tracking for customers [8] - The therapeutics business presented data on 23ME610 and 23ME1473 at major oncology conferences, with plans to share additional clinical data later in 2025 [11][12] Company Strategy and Industry Competition - The company is prioritizing membership growth in its PGS segment, leveraging telehealth, and expanding its research data business [5][9] - AI development is a key focus, with new models being developed to unlock insights from the human genome and improve therapeutic target discovery [10][11] - The company is exploring combination strategies for its clinical assets, including 23ME610, to enhance therapeutic efficacy [11][29] Management Commentary on Operating Environment and Future Outlook - Management remains optimistic about the company's progress, particularly in membership growth, cost management, and AI-driven innovation [14][19] - The company is focused on achieving adjusted EBITDA profitability and improving margins through cost discipline and revenue growth [19] - Management highlighted the potential for AI to transform human health and therapeutic development, leveraging the company's extensive database [38][39] Other Important Information - The Therapeutics Discovery Group was eliminated, but this does not impact the development of the company's two clinical assets or its ability to pursue collaborations [13] - The company is working to regain NASDAQ listing compliance and is considering a reverse stock split if necessary [32] - Management is actively discussing financing options to address liquidity challenges and extend the cash runway [34] Q&A Session Summary Question: Status update on Total Health launch - Total Health has not yet rolled out to existing customers, with a potential relaunch planned for the fall [22][23] Question: Potential for further price increases - The company has already increased subscription pricing from $29 to $69 for 23andMe+ and is exploring further efficiencies in marketing spend [25][26] Question: Impact of Therapeutics Discovery Group wind-down - The wind-down does not impact the development of the company's two clinical assets, which remain a priority [28] Question: Potential combination strategies for 23ME610 - The company is actively exploring combination strategies, including with tyrosine kinase inhibitors, and plans to present additional data later this year [29][30] Question: Plans to regain NASDAQ compliance - The company has a 180-day extension to regain compliance and is seeking shareholder approval for a reverse stock split if necessary [32] Question: Addressing liquidity challenges - The company is focusing on driving revenue growth, improving margins, and exploring financing options to extend its cash runway [34] Question: Engagement with pharmaceutical stakeholders - The company is exploring opportunities to recruit patients for clinical trials and improve trial design using polygenic risk scores [35][37] Question: AI deployment plans - AI is expected to play a significant role in improving disease prevention, management, and therapeutic discovery, leveraging the company's extensive database [38][39]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ____________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM___________ TO___________ Commission File Number 001-39587 ______________________________________ ...